What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?

Salamon, András; Zádori, Dénes; Szpisjak, László; Klivényi, Péter; Vécsei, László

doi:10.1080/14656566.2022.2060738

Cited by 18 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Entacapone, tolcapone, and opicapone are the three main COMT inhibitors. These medications work by inhibiting the COMT enzyme, which raises the blood levels of levodopa without causing it to be peripherally degraded into 3-O-methyldopa (3-OMD) [ 30 , 31 ]. Dyskinesia and diarrhea may be possible side effects [ 27 ].…”

Section: Parkinson’s Disease: Backgroundmentioning

confidence: 99%

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

et al. 2022

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disease that affects the neural, behavioral, and physiological systems of the brain. This disease is also known as tremor. The common symptoms of this disease are a slowness of movement known as ‘bradykinesia’, loss of automatic movements, speech/writing changes, and difficulty with walking at early stages. To solve these issues and to enhance the diagnostic process of PD, machine learning (ML) algorithms have been implemented for the categorization of subjective disease and healthy controls (HC) with comparable medical appearances. To provide a far-reaching outline of data modalities and artificial intelligence techniques that have been utilized in the analysis and diagnosis of PD, we conducted a literature analysis of research papers published up until 2022. A total of 112 research papers were included in this study, with an examination of their targets, data sources and different types of datasets, ML algorithms, and associated outcomes. The results showed that ML approaches and new biomarkers have a lot of promise for being used in clinical decision-making, resulting in a more systematic and informed diagnosis of PD. In this study, some major challenges were addressed along with a future recommendation.

show abstract

Section: Parkinson’s Disease: Backgroundmentioning

confidence: 99%

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The catechol‐ O ‐methyltransferase (COMT) inhibitors such as entacapone and tolcapone are selective and reversible inhibitors of COMT enzyme, and are often used in the management of PD. 184 Entacapone only inhibits the peripheral COMT enzyme though tolcapone can cross BBB and inhibit brain COMT enzyme. COMT inhibitors prolong the therapeutic effect of L‐dopa in patients with advanced PD.…”

Section: Activators Of Bdnf/trkb Signalling In Pdmentioning

confidence: 99%

“…COMT inhibitors prolong the therapeutic effect of L‐dopa in patients with advanced PD. 184 Findings from a preclinical study observed that entacapone improves hippocampal neurogenesis through activation of the BDNF–TrkB‐pCREB pathway in mice. 185 In addition, entacapone enhances hippocampal synaptic plasticity by increasing the expression of hippocampal proteins dynamin I and synapsin I which control synaptic plasticity via BDNF–TrkB.…”

Section: Activators Of Bdnf/trkb Signalling In Pdmentioning

confidence: 99%

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Ali,

Al‐Kuraishy,

Al‐Gareeb

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disorder of the brain and is manifested by motor and non‐motor symptoms because of degenerative changes in dopaminergic neurons of the substantia nigra. PD neuropathology is associated with mitochondrial dysfunction, oxidative damage and apoptosis. Thus, the modulation of mitochondrial dysfunction, oxidative damage and apoptosis by growth factors could be a novel boulevard in the management of PD. Brain‐derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase type B (TrkB) are chiefly involved in PD neuropathology. BDNF promotes the survival of dopaminergic neurons in the substantia nigra and enhances the functional activity of striatal neurons. Deficiency of the TrkB receptor triggers degeneration of dopaminergic neurons and accumulation of α‐Syn in the substantia nigra. As well, BDNF/TrkB signalling is reduced in the early phase of PD neuropathology. Targeting of BDNF/TrkB signalling by specific activators may attenuate PD neuropathology. Thus, this review aimed to discuss the potential role of BDNF/TrkB activators against PD. In conclusion, BDNF/TrkB signalling is decreased in PD and linked with disease severity and long‐term complications. Activation of BDNF/TrkB by specific activators may attenuate PD neuropathology.

show abstract

“…Entacapone, tolcapone, and opi-Capone are the three main COMT inhibitors. These medications work by inhibiting the COMT enzyme, which raises blood levels of levodopa without causing it to be peripherally degraded into 3-O-methyldopa (3-OMD) [ 105 ]. Dyskinesia and diarrhea may include possible side effects [ 103 ].…”

Section: Parkinson’s Disease: An Overviewmentioning

confidence: 99%

A Computerized Analysis with Machine Learning Techniques for the Diagnosis of Parkinson’s Disease: Past Studies and Future Perspectives

et al. 2022

View full text Add to dashboard Cite

According to the World Health Organization (WHO), Parkinson’s disease (PD) is a neurodegenerative disease of the brain that causes motor symptoms including slower movement, rigidity, tremor, and imbalance in addition to other problems like Alzheimer’s disease (AD), psychiatric problems, insomnia, anxiety, and sensory abnormalities. Techniques including artificial intelligence (AI), machine learning (ML), and deep learning (DL) have been established for the classification of PD and normal controls (NC) with similar therapeutic appearances in order to address these problems and improve the diagnostic procedure for PD. In this article, we examine a literature survey of research articles published up to September 2022 in order to present an in-depth analysis ofthe use of datasets, various modalities, experimental setups, and architectures that have been applied in the diagnosis of subjective disease. This analysis includes a total of 217 research publications with a list of the various datasets, methodologies, and features. These findings suggest that ML/DL methods and novel biomarkers hold promising results for application in medical decision-making, leading to a more methodical and thorough detection of PD. Finally, we highlight the challenges and provide appropriate recommendations on selecting approaches that might be used for subgrouping and connection analysis with structural magnetic resonance imaging (sMRI), DaTSCAN, and single-photon emission computerized tomography (SPECT) data for future Parkinson’s research.

show abstract

What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?

Cited by 18 publications

References 20 publications

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

A Computerized Analysis with Machine Learning Techniques for the Diagnosis of Parkinson’s Disease: Past Studies and Future Perspectives

Contact Info

Product

Resources

About